Comparison of Visual Fields: Humphrey Field Analyzer (HFA) SITA Strategy, SCOPE (GATE Strategy) and Humphrey MATRIX Perimeter
NCT ID: NCT01068938
Last Updated: 2016-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2008-11-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
open angle glaucoma, glaucoma suspects
risk of progression, Latanoprost monotherapy
three different perimeters: HFA, Octopus, MATRIX
visual fields
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
three different perimeters: HFA, Octopus, MATRIX
visual fields
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* distant visual acuity \> 10/20
* isocoria, pupil diameter \> 3 mm
* at least one risk of progression: optic disc (splinter) hemorrhage / cup to disc ratio (CDR) \> 0.7 / inter-eye asymmetry of CDR \>0.2 / notching of the optic disc /retinal nerve fibre layer (RNFL) defects / intraocular pressure( IOP) \>22 mmHg / central corneal thickness \< 520 µm / advanced visual field defect stage Aulhorn III / elder than 70 years
Exclusion Criteria
* diabetic retinopathy
* asthma
* HIV+ or AIDS
* history of epilepsy or significant psychiatric disease
* medications known to effect visual field sensitivity
* infections (e.g. keratitis, conjunctivitis, uveitis)
* severe dry eyes
* miotic drug
* amblyopia
* squint
* nystagmus
* albinism
* any ocular pathology, in either eye, that may interfere with the ability to obtain visual fields,disc imaging or accurate IOP readings
* keratoconus
* intraocular surgery (except for uncomplicated cataract surgery) performed \< 3 month prior to screening
* history or signs of any visual pathway affection other than glaucoma
* allergies with regard to topic glaucoma medication
* history or presence of macular disease and / or macular edema
* ocular trauma
* medications known to affect visual field sensitivity
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ulrich Schiefer
Prof. Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ulrich Schiefer, MD
Role: PRINCIPAL_INVESTIGATOR
Centre for Ophthalmology, Institute for Ophthalmic Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Ophthalmology, Institute for Ophthalmic Research
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schiefer U, Pascual JP, Edmunds B, Feudner E, Hoffmann EM, Johnson CA, Lagreze WA, Pfeiffer N, Sample PA, Staubach F, Weleber RG, Vonthein R, Krapp E, Paetzold J. Comparison of the new perimetric GATE strategy with conventional full-threshold and SITA standard strategies. Invest Ophthalmol Vis Sci. 2009 Jan;50(1):488-94. doi: 10.1167/iovs.08-2229. Epub 2008 Dec 5.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
116MIR08023
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
428/2008BO1
Identifier Type: OTHER
Identifier Source: secondary_id
X-SCOPE
Identifier Type: -
Identifier Source: org_study_id